$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000106282219000022 Filed on August 01, 2019

Income Statement

Concept	2019 Q2	2018 Q2
Revenue	$9.682M	$13.80M
YoY Change	-29.83%	14.16%
Cost Of Revenue	$1.327M	$838.0K
YoY Change	58.35%	56.05%
Gross Profit	$8.355M	$12.96M
YoY Change	-35.53%	12.21%
Gross Profit Margin	86.29%	93.93%
Selling, General & Admin	$14.30M	$16.80M
YoY Change	-14.88%	-9.07%
% of Gross Profit	171.15%	129.63%
Research & Development	$12.64M	$26.48M
YoY Change	-52.27%	-1.7%
% of Gross Profit	151.25%	204.3%
Depreciation & Amortization	$900.0K	$1.000M
YoY Change	-10.0%	0.0%
% of Gross Profit	10.77%	7.72%
Operating Expenses	$28.23M	$44.07M
YoY Change	-35.95%	-4.08%
Operating Profit	-$18.55M	-$30.27M
YoY Change	-38.74%	-9.61%
Interest Expense	$5.164M	$5.187M
YoY Change	-0.44%	221.38%
% of Operating Profit
Other Income/Expense, Net	$691.0K	$910.0K
YoY Change	-24.07%	103.13%
Pretax Income	-$23.00M	-$34.71M
YoY Change	-33.73%	-1.01%
Income Tax
% Of Pretax Income
Net Earnings	-$23.02M	-$34.55M
YoY Change	-33.38%	-0.31%
Net Earnings / Revenue	-237.74%	-250.39%
Basic Earnings Per Share	-$0.22
Diluted Earnings Per Share	-$0.22	-$326.1K
COMMON SHARES
Basic Shares Outstanding	106.3M shares	105.8M shares
Diluted Shares Outstanding	106.3M shares

Balance Sheet

Concept	2019 Q2	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$106.0M	$209.7M
YoY Change	-49.45%	-9.3%
Cash & Equivalents	$11.11M	$48.90M
Short-Term Investments	$94.90M	$194.6M
Other Short-Term Assets	$6.625M	$3.954M
YoY Change	67.55%	-61.14%
Inventory	$4.277M	$2.142M
Prepaid Expenses
Receivables	$5.580M	$4.406M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$122.5M	$220.2M
YoY Change	-44.39%	-10.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.01M	$16.77M
YoY Change	-10.52%	-9.77%
Goodwill	$44.54M	$44.54M
YoY Change	0.0%	0.0%
Intangibles	$49.24M	$51.00M
YoY Change	-3.46%	-3.35%
Long-Term Investments
YoY Change
Other Assets	$1.898M	$429.0K
YoY Change	342.42%	0.23%
Total Long-Term Assets	$110.7M	$112.7M
YoY Change	-1.83%	-3.08%
TOTAL ASSETS
Total Short-Term Assets	$122.5M	$220.2M
Total Long-Term Assets	$110.7M	$112.7M
Total Assets	$233.1M	$332.9M
YoY Change	-29.97%	-8.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.03M	$50.45M
YoY Change	-80.12%	15.04%
Accrued Expenses	$9.083M	$12.87M
YoY Change	-29.4%	17.39%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.115M	$12.90M
YoY Change	-91.35%	-14.91%
Total Short-Term Liabilities	$22.47M	$81.34M
YoY Change	-72.38%	-38.92%
LONG-TERM LIABILITIES
Long-Term Debt	$244.0M	$232.2M
YoY Change	5.06%	171.95%
Other Long-Term Liabilities	$1.325M	$265.0K
YoY Change	400.0%	-15.34%
Total Long-Term Liabilities	$245.3M	$232.5M
YoY Change	5.51%	171.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.47M	$81.34M
Total Long-Term Liabilities	$245.3M	$232.5M
Total Liabilities	$298.0M	$338.0M
YoY Change	-11.83%	31.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.516B	-$1.444B
YoY Change	5.02%	9.2%
Common Stock	$106.0K	$106.0K
YoY Change	0.0%	0.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.817M	$2.876M
YoY Change	32.72%	51.05%
Treasury Stock Shares	407.0K shares	236.0K shares
Shareholders Equity	-$64.89M	-$5.071M
YoY Change
Total Liabilities & Shareholders Equity	$233.1M	$332.9M
YoY Change	-29.97%	-8.41%

Cashflow Statement

Concept	2019 Q2	2018 Q2
OPERATING ACTIVITIES
Net Income	-$23.02M	-$34.55M
YoY Change	-33.38%	-0.31%
Depreciation, Depletion And Amortization	$900.0K	$1.000M
YoY Change	-10.0%	0.0%
Cash From Operating Activities	-$26.90M	-$52.50M
YoY Change	-48.76%	63.04%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$100.0K
YoY Change	-100.0%	0.0%
Acquisitions
YoY Change
Other Investing Activities	-$7.400M	$47.40M
YoY Change	-115.61%	-16.7%
Cash From Investing Activities	-$7.500M	$47.30M
YoY Change	-115.86%	-16.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-300.0K	-200.0K
YoY Change	50.0%	-105.41%
NET CHANGE
Cash From Operating Activities	-26.90M	-52.50M
Cash From Investing Activities	-7.500M	47.30M
Cash From Financing Activities	-300.0K	-200.0K
Net Change In Cash	-34.70M	-5.400M
YoY Change	542.59%	-119.15%
FREE CASH FLOW
Cash From Operating Activities	-$26.90M	-$52.50M
Capital Expenditures	$0.00	-$100.0K
Free Cash Flow	-$26.90M	-$52.40M
YoY Change	-48.66%	63.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	lxrx	Ipsen Maximum Sales Milestones IpsenMaximumSalesMilestones	72000000	EUR
CY2016Q3	lxrx	Ipsen Milestone Payment IpsenMilestonePayment	6400000	USD
	lxrx	Ipsen Milestone Payment IpsenMilestonePayment	6400000	USD
	lxrx	Ipsen Milestone Payment IpsenMilestonePayment	5100000	USD
CY2017Q4	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	3840000	USD
CY2017Q4	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	3840000	USD
	dei	Entity Small Business EntitySmallBusiness	false
CY2019Q2	lxrx	Buildings Collateral BuildingsCollateral	59200000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	106271927	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Registrant Name EntityRegistrantName	LEXICON PHARMACEUTICALS, INC./DE
CY2019Q2	dei	Entity Shell Company EntityShellCompany	false
CY2019Q1	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	2250000	USD
CY2019Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q2	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	5100000	USD
CY2018Q4	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	1250000	USD
	lxrx	Ipsen Product Revenue IpsenProductRevenue	1400000	USD
	lxrx	Ipsen Product Revenue IpsenProductRevenue	1300000	USD
CY2014Q4	lxrx	Conv Debt Instrument Interest Rate Stated Percentage ConvDebtInstrumentInterestRateStatedPercentage	0.0525
	lxrx	Ipsen Maximum Regulatory And Commercial Milestones IpsenMaximumRegulatoryAndCommercialMilestones	9600000	USD
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Development Deliverable IpsenRevenueAllocatedtoDevelopmentDeliverable	1700000	USD
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Committee Deliverable IpsenRevenueAllocatedtoCommitteeDeliverable	100000	USD
CY2014	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	21200000	USD
CY2015	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	1400000	USD
	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	700000	USD
	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	3100000	USD
	lxrx	Ipsen Royalty Income Lxrx IpsenRoyaltyIncome_LXRX	100000	USD
	lxrx	Ipsen Royalty Income Lxrx IpsenRoyaltyIncome_LXRX	100000	USD
CY2019Q2	lxrx	Ipsen Total Payments IpsenTotalPayments	47200000	USD
CY2015Q1	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
CY2019Q2	lxrx	Land Collateral LandCollateral	2700000	USD
CY2018Q3	lxrx	Mortgage Debt Balloon Payment Lxrx MortgageDebtBalloonPayment_LXRX	10300000	USD
CY2019Q2	lxrx	Mortgage Debt Instrument Revere Lxrx MortgageDebtInstrument_Revere_LXRX	11600000	USD
CY2018Q3	lxrx	Mortgage Debt Instrument Revere Lxrx MortgageDebtInstrument_Revere_LXRX	12900000	USD
CY2018Q3	lxrx	Mortgage Debt Interest Rate Base Plus Revere Lxrx MortgageDebtInterestRateBasePlus_Revere_LXRX	0.075
CY2018Q3	lxrx	Mortgage Debt Interest Rate Base Revere Lxrx MortgageDebtInterestRate_Base_Revere_LXRX	0.055
CY2019Q2	lxrx	Mortgage Debt Issue Costs Revere Lxrx MortgageDebtIssueCosts_Revere_LXRX	200000	USD
CY2018Q3	lxrx	Mortgage Debt Issue Costs Revere Lxrx MortgageDebtIssueCosts_Revere_LXRX	400000	USD
CY2018Q2	lxrx	Netproductrevenue Netproductrevenue	7316000	USD
	lxrx	Netproductrevenue Netproductrevenue	12776000	USD
CY2019Q2	lxrx	Netproductrevenue Netproductrevenue	8672000	USD
	lxrx	Netproductrevenue Netproductrevenue	15412000	USD
CY2015Q4	lxrx	Sanofi Commercialization Costs Fundedby Lexicon Maximum Amount SanofiCommercializationCostsFundedbyLexiconMaximumAmount	100000000	USD
CY2015Q4	lxrx	Sanofi Development Milestones SanofiDevelopmentMilestones	110000000	USD
CY2015Q4	lxrx	Sanofi Outcomes Study Milestone SanofiOutcomesStudyMilestone	100000000	USD
CY2015Q4	lxrx	Sanofi Regulatory Milestones SanofiRegulatoryMilestones	220000000	USD
CY2015Q4	lxrx	Sanofi Revenue Allocatedto Development Deliverable SanofiRevenueAllocatedtoDevelopmentDeliverable	113800000	USD
CY2015Q4	lxrx	Sanofi Revenue Allocatedto Funding Deliverable SanofiRevenueAllocatedtoFundingDeliverable	59400000	USD
CY2015Q4	lxrx	Sanofi Revenue Allocatedto License Deliverable SanofiRevenueAllocatedtoLicenseDeliverable	126800000	USD
	lxrx	Sanofi Revenue Recognized SanofiRevenueRecognized	25300000	USD
	lxrx	Sanofi Revenue Recognized SanofiRevenueRecognized	300000	USD
CY2015Q4	lxrx	Sanofi Sales Milestone Payments SanofiSalesMilestonePayments	990000000	USD
CY2015Q4	lxrx	Sanofi Upfront Payment SanofiUpfrontPayment	300000000	USD
CY2018Q2	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	16755000	USD
	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	31612000	USD
CY2019Q2	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	14263000	USD
	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	28373000	USD
CY2018Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1395000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	3050000	USD
CY2019Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1903000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	3671000	USD
CY2018Q2	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	1503000	USD
	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	2922000	USD
CY2019Q2	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	1863000	USD
	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	3506000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17759000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	10028000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5924000	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5580000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14482000	USD
CY2019Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9083000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	60006000	USD
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	60791000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12000	USD
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	86000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1447954000	USD
CY2019Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1455131000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3074000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2898000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3411000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3766000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4000	USD
CY2019Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	592000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	708000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	900000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	900000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2018Q4	us-gaap	Assets Assets	284136000	USD
CY2019Q2	us-gaap	Assets Assets	233143000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	173324000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	122459000	USD
CY2018Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	79666000	USD
CY2019Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	94871000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61661000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15044000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80386000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11106000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	80386000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	11106000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-46617000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-69280000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1880000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1371000	USD
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1327000	USD
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	106000	USD
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	106000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34373000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-76365000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22965000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44717000	USD
CY2018Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	838000	USD
CY2014Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8.442
CY2014Q4	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	118.4553
CY2017Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	150000000	USD
CY2019Q2	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	95600000	USD
CY2019Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.09
CY2019Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	2800000	USD
CY2017Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	4100000	USD
CY2018Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3395000	USD
CY2019Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2243000	USD
CY2018Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	23651000	USD
CY2019Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	24268000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	6014000	USD
CY2019Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	6014000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1853000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1811000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.72
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3237000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4119000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2019Q2	us-gaap	Goodwill Goodwill	44543000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6844000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-13842000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-419000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-344000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-25208000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-535000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	194000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-403000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-186000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-481000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3957000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	50119000	USD
CY2019Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	49236000	USD
CY2018Q2	us-gaap	Interest Expense InterestExpense	5187000	USD
	us-gaap	Interest Expense InterestExpense	10300000	USD
CY2019Q2	us-gaap	Interest Expense InterestExpense	5164000	USD
	us-gaap	Interest Expense InterestExpense	10281000	USD
	us-gaap	Interest Paid Net InterestPaidNet	6726000	USD
	us-gaap	Interest Paid Net InterestPaidNet	9610000	USD
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	884000	USD
CY2019Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	324000	USD
CY2018Q4	us-gaap	Inventory Gross InventoryGross	4680000	USD
CY2019Q2	us-gaap	Inventory Gross InventoryGross	4277000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	4680000	USD
CY2019Q2	us-gaap	Inventory Net InventoryNet	4277000	USD
CY2018Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3564000	USD
CY2019Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	3529000	USD
CY2018Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	232000	USD
CY2019Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	424000	USD
CY2018Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	160052000	USD
CY2019Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	105977000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.09
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2200000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	304000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	645000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	632000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	620000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	322000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	310541000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	298029000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	284136000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	233143000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36751000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	22469000	USD
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1115000	USD
CY2019Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	1115000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	243887000	USD
CY2019Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	243953000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1749000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1584000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	54430000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15176000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-99298000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52520000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-34549000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-76369000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-67984000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-18545000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-36014000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-23018000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-44815000	USD
	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification	14212000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	44070000	USD
	us-gaap	Operating Expenses OperatingExpenses	107156000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	28227000	USD
	us-gaap	Operating Expenses OperatingExpenses	54912000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-30272000	USD
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1878000	USD
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	553000	USD
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	600000	USD
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1325000	USD
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1300000	USD
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1900000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2100000	USD
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2668000	USD
CY2019Q2	us-gaap	Other Assets Current OtherAssetsCurrent	6625000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	285000	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1898000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-172000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	176000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	4000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	45000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	53000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	98000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	238000	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1325000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	910000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1915000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	691000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1480000	USD
CY2014Q4	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	3400000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	972000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	941000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	49638000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	106706000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	55000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	70000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15007000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	91600000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15865000	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	87500000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	392000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	104123000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1169000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	643000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26477000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	74173000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12637000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24659000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1471577000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1516392000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6404000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26236000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	860000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3299000	USD
CY2018Q2	us-gaap	Revenues Revenues	13798000	USD
	us-gaap	Revenues Revenues	39172000	USD
CY2019Q2	us-gaap	Revenues Revenues	9682000	USD
	us-gaap	Revenues Revenues	18898000	USD
CY2018Q2	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	78000	USD
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	160000	USD
CY2019Q2	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	150000	USD
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	187000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5972000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	7177000	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	79666000	USD
CY2019Q2	us-gaap	Short Term Investments ShortTermInvestments	94871000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	367000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-26405000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	-64886000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	68265000	USD
CY2018Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	42612000	USD
CY2018Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11504000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-26405000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-45687000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-64886000	USD
CY2018Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2876000	USD
CY2019Q2	us-gaap	Treasury Stock Value TreasuryStockValue	3817000	USD
CY2018Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	236000	shares
CY2019Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	407000	shares
CY2018Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	972000	USD
CY2019Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	941000	USD
CY2019Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	1200000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	4000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	98000	USD
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	105848000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	105758000	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	106272000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	106164000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of Credit Risk:</font><font style="font-family:inherit;font-size:10pt;"> Lexicon’s cash equivalents, short-term investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and short-term investments by placing investments in high-quality financial instruments. The Company’s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.  The Company has not experienced any significant credit losses to date.  </font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates:</font><font style="font-family:inherit;font-size:10pt;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001062822-19-000022-index-headers.html	Edgar Link	pending
0001062822-19-000022-index.html	Edgar Link	pending
0001062822-19-000022.txt	Edgar Link	pending
0001062822-19-000022-xbrl.zip	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lxrx-20190630.xml	Edgar Link	completed
lxrx-20190630.xsd	Edgar Link	pending
lxrx-20190630_cal.xml	Edgar Link	unprocessable
lxrx-20190630_def.xml	Edgar Link	unprocessable
lxrx-20190630_lab.xml	Edgar Link	unprocessable
lxrx-20190630_pre.xml	Edgar Link	unprocessable
lxrx630201910-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2019 Q2 Form 10-Q Financial Statement

#000106282219000022 Filed on August 01, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2019 Q2 Form 10-Q Financial Statement

#000106282219000022 Filed on August 01, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx